Many thanks to Juergen Eckhardt for highlighting the work we’re doing at Cimeio Therapeutics to develop curative therapies for blood cancers like AML. Exposure like this helps us to build the momentum needed to advance the field and make the promise of our epitope #shielding a reality for patients and their families. https://lnkd.in/e2fah4zU
Head of Leaps by Bayer and Head of Pharmaceuticals Business Development and Licensing. Executive Vice President, MD, MBA
What a full circle moment: In line with my newest Forbes column investigating new approaches to #BloodCancer therapy, I learned about the work of researchers at the University of Basel, where my own academic career in medicine began many moons ago. Standard practice has relied on treating blood cancers by using very high doses of #chemotherapy to wipe out the patient’s entire blood cell production systems along with the cancerous cells - a grueling approach with many side effects for patients. Today, novel approaches like #baseediting create renewed hope for patients and physicians, potentially offering future treatment options with minimal side effects. In my newest op-ed, I explore the groundbreaking work of: Caribou Biosciences, a company developing their own off-the-shelf CAR T-cell therapies to treat blood cancer. Cimeio Therapeutics, transforming #immunotherapy for hematologic disorders. I also invite you to listen to prominent voices such as: Fyodor Urnov, Professor of molecular and cell biology at the University of California, Berkeley. Lukas Jeker, Professor of the University of Basel and Founder of Cimeo. Rachel Haurwitz, President and CEO of Caribou Biosciences. Join me in exploring the cutting-edge advancements in #BloodCancer therapy and the innovative minds driving these breakthroughs - read below. Which other companies should I consider for a potential sequel column on blood cancer therapies? Feel free to share in the comments below: